Purpose: In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[F]fluoro-D-glucose ([F]F-FDG) positron emission tomography (PET)/computed tomography (CT) after autologous stem cell transplantation (ASCT) in lymphoma. . A total of 76 lymphoma patients who benefited from [F]F-FDG PET-CT (within 3 months and 3-6 months) after ASCT in our institution between April 2010 and December 2019 were enrolled in this retrospective study. These abovementioned patients were divided into two groups based on the Deauville criteria. The Kaplan-Meier method was used in survival analysis, and the log-rank method was adopted in comparison. Prognostic factor analysis was performed by the Cox regression model.
Results: Positive post-ASCT [F]F-FDG PET-CT was associated with lower progression-free survival (PFS) and overall survival (OS) ( = 0.001 and = 0.022, respectively). Univariate analysis showed the post-ASCT PET-CT result was the only independent factor associated with PFS ( = 0.002). Both the number of previous treatments and post-ASCT PET-CT result had a different impact on OS ( = 0.040 and = 0.028, respectively). Multivariate analysis showed the post-ASCT PET-CT result was the only independent factor associated with OS ( = 0.028). The results showed no significant change from the abovementioned results when DS < 3 was defined as the negative result. For patients who had a PET-CT scan within 3-6 months after ASCT, the negative PET-CT group had a better prognosis including PFS and OS ( = 0.009 and = 0.025, respectively). However, among the patients receiving PET-CT within 3 months, the result was not statistically significant ( = 0.064 and = 0.445, respectively).
Conclusion: Collectively, we found that the post-ASCT [F]F-FDG PET-CT was a strong indicator for PFS and OS, and a time window of 3-6 months was appropriate for post-ASCT [F]F-FDG PET-CT. Trial registration number: ChiCTR2100042745.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075696 | PMC |
| http://dx.doi.org/10.1155/2021/5510825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent COVID-19 Infection in a Refractory/Classical Hodgkin's Lymphoma Patient Undergoing Autologous Stem Cell Transplantation: A Case Report.
Cureus
October 2023
Department of Pathology and Laboratory Medicine, Division of Molecular Medicine, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, SAU.
Patients with challenging hematological malignancies like classic Hodgkin lymphoma (cHL) can be further complicated when affected by a concurrent coronavirus disease-2019 (COVID-19) infection and often face unique and complex management and outcomes. In this case report, we describe a refractory or relapsed classic Hodgkin lymphoma patient with a recurrent infection of COVID-19 three times preceding chemotherapy. A 52-year-old female presented to our hospital with a second incidence of COVID-19 and a complaint of fever, anorexia, night sweats, and abdominal lymphadenopathy, for which she was diagnosed with mixed cellularity classic Hodgkin lymphoma.
View Article and Find Full Text PDFPrognostic significance of extramedullary disease (EMD) detected on pre-transplant F-FDG PET/CT in patients with multiple myeloma: Results of PIPET-M trial.
Med J Armed Forces India
September 2023
Professor & Head (Clinical Hematology & Medical Oncology), Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Background: It is difficult to prognosticate the post-Autologous Stem Cell Transplant (ASCT) responses in multiple myeloma (MM) with the currently available prognostication models. F-FDGPET/CT has numerous advantages to prognosticate the post-transplant responses by assessing extramedullary disease (EMD) in addition to the extent of active disease. We aimed at identifying the prognostic value of EMD in predicting progression-free survival (PFS) and overall survival (OS).
View Article and Find Full Text PDFIntegrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
Blood Cancer J
March 2023
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated with improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in combination with functional imaging remains to be validated. We performed a retrospective analysis on MM patients who underwent frontline autologous stem cell transplant (ASCT).
View Article and Find Full Text PDFBeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study.
J Clin Med
June 2022
Department of Medical Oncology, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
(1) Introduction: BEAM is a high-dose chemotherapy (HDCT) frequently administered before autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). Bendamustine replacing BCNU (BeEAM) is similarly effective at lower toxicities. However, relapse remains the major cause of death in DLBCL.
View Article and Find Full Text PDFBrentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Hematol Oncol
February 2022
Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post-ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression-free survival (PFS) to cHL patients at high risk of relapse.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!